Loading…

Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study

The aim of the study was to evaluate the efficacy of methotrexate treatment in patients with ankylosing spondylitis in a 3-year open trial. Seventeen patients, 14 men and three women (mean age 32.7+/-8.9 years), suffering from ankylosing spondylitis and non-responders to treatment with sulphasalazin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2000-01, Vol.19 (2), p.114-117
Main Authors: Biasi, D, Carletto, A, Caramaschi, P, Pacor, M L, Maleknia, T, Bambara, L M
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c316t-56462e6e9658a4434ad3115e9ded4cf51d321f1a79b2f001cf76f0a19934a7e13
cites
container_end_page 117
container_issue 2
container_start_page 114
container_title Clinical rheumatology
container_volume 19
creator Biasi, D
Carletto, A
Caramaschi, P
Pacor, M L
Maleknia, T
Bambara, L M
description The aim of the study was to evaluate the efficacy of methotrexate treatment in patients with ankylosing spondylitis in a 3-year open trial. Seventeen patients, 14 men and three women (mean age 32.7+/-8.9 years), suffering from ankylosing spondylitis and non-responders to treatment with sulphasalazine, were enrolled in our study. Sixteen of them were evaluable at the end of the study. Methotrexate (7.5-10 mg/week) was administered for 3 years. Efficacy was evaluated on the basis of clinical and laboratory variables, radiographic signs of disease progression and daily dosage of indomethacin. We obtained a good and relatively prompt clinical response except for peripheral arthritis and iridocyclitis; in fact, after 3 months of methotrexate treatment a significant amelioration of the following parameters was observed: visual analogue scale for the evaluation of both night pain and general well-being, Shober's test, occiput-wall distance, fingertip to floor, erythrocyte sedimentation rate, C-reactive protein level and daily dose of indomethacin. A further improvement was obtained during the subsequent period. Radiographs of the spine and sacroiliac joints did not show any signs of disease progression. Side-effects were a transitory elevation of transaminases (four cases) and slight hypogammaglobulinaemia (one case). Methotrexate treatment may be useful in ankylosing spondylitis, but a combined treatment might be indicated for patients with peripheral arthritis.
doi_str_mv 10.1007/s100670050027
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_881385282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418628141</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-56462e6e9658a4434ad3115e9ded4cf51d321f1a79b2f001cf76f0a19934a7e13</originalsourceid><addsrcrecordid>eNpV0N9LwzAQB_AgipvTR18l-F7NNW3S-CZj_oCBL_omlKy9uM61qUkK639vxvagL3ccfLg7voRcA7sDxuS9j1VIxnLGUnlCppDxLFEqU6dkyqRkCQdVTMiF9xsWSaHgnEyASQUihSn5XBjTVLoaqTW0xbC2weFOB6RNR8MaaRx1aLELe6C773FrfdN9Ud_brh63TWj8A9WROsRkRO2o7bGjPgz1eEnOjN56vDr2Gfl4WrzPX5Ll2_Pr_HGZVBxESHKRiRQFKpEXOov_65oD5KhqrLPK5FDzFAxoqVapYQwqI4VhGpSKVCLwGbk97O2d_RnQh3JjB9fFk2VRAC_ytEgjSg6octZ7h6bsXdNqN5bAyn2U5b8oo785Lh1WLdZ_9CE7_gu6925D</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881385282</pqid></control><display><type>article</type><title>Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study</title><source>Springer Nature</source><creator>Biasi, D ; Carletto, A ; Caramaschi, P ; Pacor, M L ; Maleknia, T ; Bambara, L M</creator><creatorcontrib>Biasi, D ; Carletto, A ; Caramaschi, P ; Pacor, M L ; Maleknia, T ; Bambara, L M</creatorcontrib><description>The aim of the study was to evaluate the efficacy of methotrexate treatment in patients with ankylosing spondylitis in a 3-year open trial. Seventeen patients, 14 men and three women (mean age 32.7+/-8.9 years), suffering from ankylosing spondylitis and non-responders to treatment with sulphasalazine, were enrolled in our study. Sixteen of them were evaluable at the end of the study. Methotrexate (7.5-10 mg/week) was administered for 3 years. Efficacy was evaluated on the basis of clinical and laboratory variables, radiographic signs of disease progression and daily dosage of indomethacin. We obtained a good and relatively prompt clinical response except for peripheral arthritis and iridocyclitis; in fact, after 3 months of methotrexate treatment a significant amelioration of the following parameters was observed: visual analogue scale for the evaluation of both night pain and general well-being, Shober's test, occiput-wall distance, fingertip to floor, erythrocyte sedimentation rate, C-reactive protein level and daily dose of indomethacin. A further improvement was obtained during the subsequent period. Radiographs of the spine and sacroiliac joints did not show any signs of disease progression. Side-effects were a transitory elevation of transaminases (four cases) and slight hypogammaglobulinaemia (one case). Methotrexate treatment may be useful in ankylosing spondylitis, but a combined treatment might be indicated for patients with peripheral arthritis.</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s100670050027</identifier><identifier>PMID: 10791621</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Adult ; Alanine Transaminase - blood ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Aspartate Aminotransferases - blood ; C-Reactive Protein - metabolism ; Drug Evaluation ; Drug therapy ; Drug Therapy, Combination ; Female ; Humans ; Indomethacin - therapeutic use ; Male ; Methotrexate - adverse effects ; Methotrexate - therapeutic use ; Middle Aged ; Pain Measurement ; Safety ; Spondylitis, Ankylosing - blood ; Spondylitis, Ankylosing - drug therapy ; Spondylitis, Ankylosing - physiopathology ; Sulfasalazine - therapeutic use</subject><ispartof>Clinical rheumatology, 2000-01, Vol.19 (2), p.114-117</ispartof><rights>Clinical Rheumatology 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-56462e6e9658a4434ad3115e9ded4cf51d321f1a79b2f001cf76f0a19934a7e13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10791621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Biasi, D</creatorcontrib><creatorcontrib>Carletto, A</creatorcontrib><creatorcontrib>Caramaschi, P</creatorcontrib><creatorcontrib>Pacor, M L</creatorcontrib><creatorcontrib>Maleknia, T</creatorcontrib><creatorcontrib>Bambara, L M</creatorcontrib><title>Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><description>The aim of the study was to evaluate the efficacy of methotrexate treatment in patients with ankylosing spondylitis in a 3-year open trial. Seventeen patients, 14 men and three women (mean age 32.7+/-8.9 years), suffering from ankylosing spondylitis and non-responders to treatment with sulphasalazine, were enrolled in our study. Sixteen of them were evaluable at the end of the study. Methotrexate (7.5-10 mg/week) was administered for 3 years. Efficacy was evaluated on the basis of clinical and laboratory variables, radiographic signs of disease progression and daily dosage of indomethacin. We obtained a good and relatively prompt clinical response except for peripheral arthritis and iridocyclitis; in fact, after 3 months of methotrexate treatment a significant amelioration of the following parameters was observed: visual analogue scale for the evaluation of both night pain and general well-being, Shober's test, occiput-wall distance, fingertip to floor, erythrocyte sedimentation rate, C-reactive protein level and daily dose of indomethacin. A further improvement was obtained during the subsequent period. Radiographs of the spine and sacroiliac joints did not show any signs of disease progression. Side-effects were a transitory elevation of transaminases (four cases) and slight hypogammaglobulinaemia (one case). Methotrexate treatment may be useful in ankylosing spondylitis, but a combined treatment might be indicated for patients with peripheral arthritis.</description><subject>Adult</subject><subject>Alanine Transaminase - blood</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Aspartate Aminotransferases - blood</subject><subject>C-Reactive Protein - metabolism</subject><subject>Drug Evaluation</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Indomethacin - therapeutic use</subject><subject>Male</subject><subject>Methotrexate - adverse effects</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Pain Measurement</subject><subject>Safety</subject><subject>Spondylitis, Ankylosing - blood</subject><subject>Spondylitis, Ankylosing - drug therapy</subject><subject>Spondylitis, Ankylosing - physiopathology</subject><subject>Sulfasalazine - therapeutic use</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpV0N9LwzAQB_AgipvTR18l-F7NNW3S-CZj_oCBL_omlKy9uM61qUkK639vxvagL3ccfLg7voRcA7sDxuS9j1VIxnLGUnlCppDxLFEqU6dkyqRkCQdVTMiF9xsWSaHgnEyASQUihSn5XBjTVLoaqTW0xbC2weFOB6RNR8MaaRx1aLELe6C773FrfdN9Ud_brh63TWj8A9WROsRkRO2o7bGjPgz1eEnOjN56vDr2Gfl4WrzPX5Ll2_Pr_HGZVBxESHKRiRQFKpEXOov_65oD5KhqrLPK5FDzFAxoqVapYQwqI4VhGpSKVCLwGbk97O2d_RnQh3JjB9fFk2VRAC_ytEgjSg6octZ7h6bsXdNqN5bAyn2U5b8oo785Lh1WLdZ_9CE7_gu6925D</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>Biasi, D</creator><creator>Carletto, A</creator><creator>Caramaschi, P</creator><creator>Pacor, M L</creator><creator>Maleknia, T</creator><creator>Bambara, L M</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20000101</creationdate><title>Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study</title><author>Biasi, D ; Carletto, A ; Caramaschi, P ; Pacor, M L ; Maleknia, T ; Bambara, L M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-56462e6e9658a4434ad3115e9ded4cf51d321f1a79b2f001cf76f0a19934a7e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Alanine Transaminase - blood</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Aspartate Aminotransferases - blood</topic><topic>C-Reactive Protein - metabolism</topic><topic>Drug Evaluation</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Indomethacin - therapeutic use</topic><topic>Male</topic><topic>Methotrexate - adverse effects</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Pain Measurement</topic><topic>Safety</topic><topic>Spondylitis, Ankylosing - blood</topic><topic>Spondylitis, Ankylosing - drug therapy</topic><topic>Spondylitis, Ankylosing - physiopathology</topic><topic>Sulfasalazine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Biasi, D</creatorcontrib><creatorcontrib>Carletto, A</creatorcontrib><creatorcontrib>Caramaschi, P</creatorcontrib><creatorcontrib>Pacor, M L</creatorcontrib><creatorcontrib>Maleknia, T</creatorcontrib><creatorcontrib>Bambara, L M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Biasi, D</au><au>Carletto, A</au><au>Caramaschi, P</au><au>Pacor, M L</au><au>Maleknia, T</au><au>Bambara, L M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study</atitle><jtitle>Clinical rheumatology</jtitle><addtitle>Clin Rheumatol</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>19</volume><issue>2</issue><spage>114</spage><epage>117</epage><pages>114-117</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>The aim of the study was to evaluate the efficacy of methotrexate treatment in patients with ankylosing spondylitis in a 3-year open trial. Seventeen patients, 14 men and three women (mean age 32.7+/-8.9 years), suffering from ankylosing spondylitis and non-responders to treatment with sulphasalazine, were enrolled in our study. Sixteen of them were evaluable at the end of the study. Methotrexate (7.5-10 mg/week) was administered for 3 years. Efficacy was evaluated on the basis of clinical and laboratory variables, radiographic signs of disease progression and daily dosage of indomethacin. We obtained a good and relatively prompt clinical response except for peripheral arthritis and iridocyclitis; in fact, after 3 months of methotrexate treatment a significant amelioration of the following parameters was observed: visual analogue scale for the evaluation of both night pain and general well-being, Shober's test, occiput-wall distance, fingertip to floor, erythrocyte sedimentation rate, C-reactive protein level and daily dose of indomethacin. A further improvement was obtained during the subsequent period. Radiographs of the spine and sacroiliac joints did not show any signs of disease progression. Side-effects were a transitory elevation of transaminases (four cases) and slight hypogammaglobulinaemia (one case). Methotrexate treatment may be useful in ankylosing spondylitis, but a combined treatment might be indicated for patients with peripheral arthritis.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>10791621</pmid><doi>10.1007/s100670050027</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0770-3198
ispartof Clinical rheumatology, 2000-01, Vol.19 (2), p.114-117
issn 0770-3198
1434-9949
language eng
recordid cdi_proquest_journals_881385282
source Springer Nature
subjects Adult
Alanine Transaminase - blood
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Aspartate Aminotransferases - blood
C-Reactive Protein - metabolism
Drug Evaluation
Drug therapy
Drug Therapy, Combination
Female
Humans
Indomethacin - therapeutic use
Male
Methotrexate - adverse effects
Methotrexate - therapeutic use
Middle Aged
Pain Measurement
Safety
Spondylitis, Ankylosing - blood
Spondylitis, Ankylosing - drug therapy
Spondylitis, Ankylosing - physiopathology
Sulfasalazine - therapeutic use
title Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A47%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20methotrexate%20in%20the%20treatment%20of%20ankylosing%20spondylitis:%20a%20three-year%20open%20study&rft.jtitle=Clinical%20rheumatology&rft.au=Biasi,%20D&rft.date=2000-01-01&rft.volume=19&rft.issue=2&rft.spage=114&rft.epage=117&rft.pages=114-117&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s100670050027&rft_dat=%3Cproquest_cross%3E2418628141%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-56462e6e9658a4434ad3115e9ded4cf51d321f1a79b2f001cf76f0a19934a7e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881385282&rft_id=info:pmid/10791621&rfr_iscdi=true